How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,862 results for

Breast Cancer in Men

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer (PubMed)

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer Cancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostate cancer.

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

2. Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer (...) with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: June 29, 2016 Project Number: RA0855-000 Product Line: Research Type: Other Diagnostics Report Type: Reference List Result type: Report Question In the adjuvant treatment setting, what is the clinical effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Understanding breast cancer in men

Understanding breast cancer in men canceraustralia.gov.au Can men really get breast cancer? It may come as a surprise to know that men can develop breast cancer. While breast cancer is uncommon in men, it’s important for men who find a change in their breasts not to let embarrassment or uncertainty prevent them from seeing their doctor without delay. Early detection and treatment are the best way to survive the disease. About breast cancer in men In 2012, there were 116 men diagnosed (...) with breast cancer in Australia. 1 Around 90% of men are diagnosed with breast cancer after the age of 50. 1 Although breast cancer in men accounts for less than 1% of all breast cancers, it’s just as important for men as for women to see your doctor without delay if you find a breast change. 1 I had quite a few men say to me ‘that’s a woman’s disease’ and I had to say ‘no it’s not, you could get it too. What is breast cancer in men? Breast cancer in men is the same disease as that which affects women

2016 Cancer Australia

4. Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes. (PubMed)

Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes. Background Male breast cancer incidence is rising. There may be a potential role in selective screening in men at elevated risk for breast cancer, but the effectiveness of such screening remains unexplored. Purpose To evaluate patterns of male breast imaging utilization, to determine high-risk screening outcomes, and to delineate risk factors associated (...) with cancer diagnosis. Materials and Methods This retrospective study reviewed consecutive male breast imaging examinations over a 12-year period (between 2005-2017). Examination indications, biopsy recommendations, and pathologic results were correlated with patient characteristics. Fisher exact test, Mann-Whitney test, Spearman correlation, and logistic regression were used for statistical analysis. Results A total of 1869 men (median age, 55 years; range, 18-96 years) underwent 2052 examinations

2019 Radiology

5. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International (...) disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human

2018 European Medicines Agency - EPARs

6. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Familial breast cancer: classification, care Familial breast cancer: classification, care and managing breast cancer and related and managing breast cancer and related risks in people with a family history of risks in people with a family history of breast cancer breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164 © NICE 2018 (...) NICE recommendations wherever possible. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 48Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Clinical significance of a family history of breast cancer 5 1.2 Information and support 8 1.3 Care

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015. (PubMed)

Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015. Male Breast Cancer (MBC) is rare, which makes its understanding and treatment be extrapolated from what is known about the occurrence in women, with few epidemiological studies, with few epidemiological studies. Therefore, the aim of the present paper was to study breast cancer mortality in adult males in Brazil and its administrative regions between 2005 and 2015.Ecological study with data on MBC

Full Text available with Trip Pro

2019 BMC Cancer

8. Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. (PubMed)

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers. Low incidence of breast cancer in men (BCM) (< 1% of all breast cancers) has led to a paucity of outcome data. This study evaluated the impact of age on BCM outcomes.For this study, BCM patients treated between 2000 and 2011 were stratified by age (≤ 65 or > 65 years). Kaplan-Meier methods were used to compare overall survival (OS) and breast cancer-specific survival (BCSS (...) ). Competing-risk methods analyzed time to second primary cancers (SPCs), with any-cause death treated as a competing risk.The study identified 152 BCM patients with a median age of 64 years (range 19-96 years). The median body mass index (BMI) was 28 kg/m2. Men age 65 years or younger (n = 78, 51%) were more overweight/obese than men older than 65 years (n = 74, 49%) (89% vs 74%, respectively; P = 0.008). Both groups had similar nodal metastases rates (P = 0.4), estrogen receptor positivity (P = 1

2018 Annals of Surgical Oncology

9. Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines

Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines (...) CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal

2014 Health Technology Assessment (HTA) Database.

10. Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines

Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines (...) CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical

2014 Health Technology Assessment (HTA) Database.

11. Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer

Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03100981 Recruitment Status : Completed First Posted : April 4, 2017 Last Update Posted : January 8, 2019 Sponsor: University of Aarhus

2017 Clinical Trials

12. Unmet needs of men with breast cancer. (PubMed)

Unmet needs of men with breast cancer. Because of the rarity of male breast cancer (MBC) many men are unaware that the disease exists. This leads both to delay in presentation and severe distress after diagnosis concerning loss of masculinity and fear about the future. The informational and emotional support needs of men with breast cancer are often not met and many will have undiagnosed and untreated psychological morbidity. There is a pressing need for collaboration and the setting up (...) national networks to improve both the treatment and quality of life of men with breast cancer.Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

2018 European Journal of Surgical Oncology

13. Molecular Characterization and Mortality From Breast Cancer in Men. (PubMed)

Molecular Characterization and Mortality From Breast Cancer in Men. Purpose Limited data exist on the molecular biology, treatment, and outcomes of breast cancer in men, and much of our understanding in this area remains largely an extrapolation from data in women with breast cancer. Materials and Methods We studied men and women with hormone receptor-positive breast cancer and the 21-gene Breast Recurrence Score (RS) results. Differences in clinical characteristics and gene expression were (...) determined, and distribution of RS results was correlated with 5-year breast cancer-specific survival (BCSS) and overall survival. Results There were 3,806 men and 571,115 women. Men were older than women (mean age, 64.2 v 59.1 years; P < .001). RS < 18 predominated in both genders, but RS ≥ 31 was more frequent in men (12.4% v 7.4%; P < .001), as were very low scores (RS < 11; 33.8% v 22.1%; P < .001). Mean gene expression was higher in men for the estrogen receptor (ER), proliferation, and invasion

Full Text available with Trip Pro

2018 Journal of Clinical Oncology

14. Men seeking counselling in a Breast Cancer Risk Evaluation Clinic (PubMed)

Men seeking counselling in a Breast Cancer Risk Evaluation Clinic Hereditary breast and ovary cancer syndrome affects both genders but little is known about the uptake of genetic services by men. The objective of this study is to characterise the male population counselled through a multidisciplinary breast/ovarian program.Descriptive analysis of male patients counselled from January 2000 to December 2015. Data in this analysis include new cancer diagnoses during prospective follow up.From (...) for testing. Both HCF and non-HCF included patients with previous cancer diagnoses: HCF- Breast Cancer (BC) - 18; prostate cancer (PC) - 13; melanoma - 1; others - 7) and non-HCF (BC - 77; PC - 20; gastric cancer (GC) - 1; melanoma - 8; bladder cancer - 1; others - 22). From the 121 MC identified (including the TP53 and CHEK2 carriers), 97 patients (80.2%) adhered to prospective surveillance. With a median follow-up of 36.9 months, 17 cancers were diagnosed in 14 patients, PC being the most frequently

Full Text available with Trip Pro

2018 Ecancermedicalscience

15. “Guys Don’t Have Breasts”: The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer (PubMed)

“Guys Don’t Have Breasts”: The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer Men with BRCA1 or BRCA2 gene mutations are at increased risk of developing breast cancer and may have an indication for breast cancer screening using mammography. Since breast cancer is often viewed as a woman's disease, visibilizing and understanding men's experience of having a BRCA mutation and specifically, of screening for breast cancer through mammography, were (...) with a purposive sample of 15 male participants recruited from the Male Oncology Research and Education (MORE) Program. This article reports findings about participants' use of gender-specific language to describe their breasts, awareness of the ways in which their bodies changed overtime, and experiences of undergoing mammograms. This study is the first to describe men with BRCA's perceptions of their breasts and experiences of mammography in a high-risk cancer screening clinic. This study sheds light

Full Text available with Trip Pro

2018 American journal of men's health

16. Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Patients—A Mixed Methods Analysis (PubMed)

Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Patients—A Mixed Methods Analysis Male breast cancer (MBC) is rare and known as a typical woman's disease. This study is part of the N-MALE project (Male breast cancer: patient's needs in prevention, diagnosis, treatment, rehabilitation and follow-up-care) and aims to investigate how MBC patients (MBCP) feel about suffering from a "woman's disease," what character the stigmatization has, and how it can be prospectively (...) reduced. Therefore, a mixed methods design is applied including data of N = 27 qualitative interviews with MBCP and quantitative data of N = 100 MBCP. Findings identify a diverse picture, as stigmatization varies between contexts and patients: Most stigmatization concentrates on sexual stigmatization and ignorance of MBC and mostly occurs in cancer care systems and work-related contexts. The level of stigmatization varies with age and amount of treatment methods received, as reported within

Full Text available with Trip Pro

2018 American journal of men's health

17. Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review. (PubMed)

Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review. 28761315 2018 11 13 1013-9087 29 4 2017 Aug Annals of dermatology Ann Dermatol Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review. 525-528 10.5021/ad.2017.29.4.525 Kim Min-Woo MW Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. Park Hyun-Sun HS Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. Park Jong Seo JS Department of Dermatology (...) , SMG-SNU Boramae Medical Center, Seoul, Korea. Koh Seong-Joon SJ Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea. Cho Soyun S Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. eng Journal Article 2017 06 21 Korea (South) Ann Dermatol 8916577 1013-9087 CONFLICTS OF INTEREST: The authors have nothing to disclose. 2016 06 28 2016 08 25 2016 08 29 2017 8 2 6 0 2017 8 2 6 0 2017 8 2 6 1 ppublish 28761315 10.5021/ad.2017.29.4.525 PMC5500732 Cancer

Full Text available with Trip Pro

2017 Annals of dermatology

18. Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: A population-based study. (PubMed)

Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: A population-based study. Male breast cancer (MaBC) is an understudied disease; information about locoregional treatment and outcomes in patients with early stage is unknown. We aimed to analyse patient characteristics, locoregional treatment and overall survival (OS) of T1a,b,cN0M0 male breast cancer.We evaluated men with T1a,b,cN0M0 breast cancer reported to Surveillance, Epidemiology, and End Results program (...) ). Univariate analysis showed that patients with T1c, no surgery and 0 LNE had worse prognosis. In multivariate analysis, older age (hazard ratio [HR] 11.09), grade 3/4 tumours (HR 1.7), no surgery (HR 3.3), 0 LNE (HR 5.1) and unmarried patients (HR 1.7) had significantly shorter OS. There were no differences in OS between breast conservation versus mastectomy and 1-5 LNE versus > 5 LNE.Men with early breast cancer have a favourable OS. However, older age, higher grade, no breast surgery, no LNE

2017 European Journal of Cancer

19. Men and women show similar survival outcome in stage IV breast cancer. (PubMed)

Men and women show similar survival outcome in stage IV breast cancer. To evaluate the clinicopathological features, patterns of distant metastases, and survival outcome between stage IV male breast cancer (MBC) and female breast cancer (FBC).Patients diagnosed with stage IV MBC and FBC between 2010 and 2013 were included using the Surveillance, Epidemiology, and End Results program. Univariate and multivariate Cox regression analyses were used to analyze risk factors for overall survival (OS

2017 Breast

20. Views of Somali women and men on the use of faith-based messages promoting breast and cervical cancer screening for Somali women: a focus-group study. (PubMed)

Views of Somali women and men on the use of faith-based messages promoting breast and cervical cancer screening for Somali women: a focus-group study. Screening rates for breast and cervical cancer for Muslim women in the United States are low, particularly for first-generation immigrants. Interpretations of the Muslim faith represent some of the barriers for breast and cervical cancer screening. Working to understand how faith influences breast and cervical screening for Somali women (...) , and working with the community to identify and utilize faith-based assets for promoting screening, may lead to life-saving changes in screening behaviors.We partnered with an Imam to develop faith-based messages addressing the concerns of modesty and predetermination and promoting cancer testing and screening. A total of five focus groups were convened, with 34 Somali women (three groups) and 20 Somali men (two groups). Each focus group first discussed participant views of breast and cervical cancer

Full Text available with Trip Pro

2017 BMC Public Health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>